Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Nanologica AB ( (SE:NICA) ).
Nanologica AB has published an information document tied to recently resolved directed share issues totaling about SEK 13.7 million and a rights issue of roughly SEK 82.5 million before costs. The document, prepared under the EU Prospectus Regulation and registered with the Swedish Financial Supervisory Authority, is now available on the company’s and Bergs Securities’ websites, with application forms for subscription without preferential rights also provided online.
The rights issue follows board and shareholder approval and comes with a detailed timetable, including a subscription period from 11 to 25 March 2026 and trading in subscription rights and BTAs on Nasdaq Stockholm. By securing new equity capital through these offerings, Nanologica aims to strengthen its financial base to support continued growth of its peptide drug purification business, potentially reinforcing its position in the expanding market for diabetes and obesity treatments and offering existing shareholders an opportunity to participate in the company’s next phase.
The most recent analyst rating on (SE:NICA) stock is a Sell with a SEK0.36 price target. To see the full list of analyst forecasts on Nanologica AB stock, see the SE:NICA Stock Forecast page.
More about Nanologica AB
Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells advanced chromatographic consumables to pharmaceutical manufacturers. Its products are tailored for purification of peptide drugs such as insulin and GLP-1 analogues, aiming to improve productivity and lower costs in a growing global niche driven by rising demand for diabetes and obesity treatments.
By enhancing purification efficiency and product lifetime, Nanologica seeks to make peptide-based therapies more cost-effective and widely accessible. Headquartered in Södertälje and listed on Nasdaq Stockholm’s main market under the ticker NICA, the company positions itself as an enabler of broader access to life-saving drugs worldwide.
Average Trading Volume: 199,252
Technical Sentiment Signal: Sell
Current Market Cap: SEK35.25M
For an in-depth examination of NICA stock, go to TipRanks’ Overview page.